By | Reuters | 3 months 3 days ago | Health
(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.
By | ScienceDaily | 3 months 3 days ago | Health
A new study compares outcomes of 5,752 small-cell lung cancer patients who received whole-brain radiation therapy (WBRT) with those of 200 patients who received stereotactic radiosurgery (SRS), finding that the median overall survival was actually longer with SRS (10.8 months with SRS versus 7.1 months with WBRT).
By | WebMD Health | 3 months 3 days ago | Health
The combination treatment also drove down the risk that the cancer would spread by nearly as much, added the research team from NYU Langone Health in New York City.
By Maggie Fox and Felix Gussone, MD and Judy Silverman | NBC News | 3 months 3 days ago | Health
Combinations, pre-surgery treatment both help stop cancer spread
By | FOX | 3 months 3 days ago | Health
For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer.
By | ABC News | 3 months 3 days ago | Health
New research suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common cancer types